/Investor DB

Bioverge — 2024 Investments

1 investments dated 2024 · listed companies and verified rows first · show all

EnClear Therapiesencleartherapies.cominFeb 2024

EnClear Therapies is a bio/med-tech company developing the EnTrega CSF platform, focused on cerebrospinal fluid-related therapies.

BiotechDigital HealthHealthtechMedical DevicesCambridge, US

Anthony DePasqua(Executive Officer, Director)inKevin Kalish(COO)inMarcie Glicksman(VP Biology)inWilliam Gormley(CMO)Jason Camm(Director)Kasper Roet(Director)in

Co-investors20/20 HealthCare Partners LLCDolby Family VenturesFlucas VenturesTachyon VenturesVU Venture PartnersAmgen Ventures+1 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.